Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2018 06:00 ET | Source: Mesoblast Limited

Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast

NEW YORK and MELBOURNE, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all...
July 17, 2018 06:32 ET | Source: Mesoblast Limited

Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group

NEW YORK and MELBOURNE, Australia, July 17, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a strategic alliance with one of China’s...
July 11, 2018 06:00 ET | Source: Mesoblast Limited

Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

NEW YORK and MELBOURNE, Australia, July 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more...
July 02, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, July 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C....
June 21, 2018 06:00 ET | Source: Mesoblast Limited

Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting

NEW YORK and MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L,...
June 19, 2018 06:00 ET | Source: Mesoblast Limited

U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board

NEW YORK and MELBOURNE, Australia, June 19, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish...
May 30, 2018 19:32 ET | Source: Mesoblast Limited

Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018

MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced strong financial results for the nine months ended March 31, 2018 and...
May 30, 2018 18:41 ET | Source: Mesoblast Limited

Mesoblast Appoints New Chief Financial Officer

MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer,...
May 29, 2018 15:21 ET | Source: Mesoblast Limited

Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018

NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended March 31, 2018 in a webcast...
May 29, 2018 06:00 ET | Source: Mesoblast Limited

Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cell-based Immunotherapies for Solid Cancers

NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to...